Literature DB >> 8287615

Comparison of techniques for measurement of gelatinases/type IV collagenases: enzyme-linked immunoassays versus substrate degradation assays.

S Zucker1, P Mancuso, B DiMassimo, R M Lysik, C Conner, C L Wu.   

Abstract

Radiolabeled substrate degradation assays and gelatin zymography are routinely employed to assay 72 kDa gelatinase A (MMP-2) and 92 kDa gelatinase B (MMP-9) in biological fluids. Enzyme-linked immunosorbent assays (ELISA) have recently been developed for the quantitation of these matrix metalloproteinases (MMP). In this study, we have compared ELISA to standard substrate degradation assays for measurement of MMP-2 and MMP-9 in human plasma and tumor-conditioned media. Gelatin Sepharose chromatography and gel filtration chromatography were employed as partial purification procedures for MMP-2 and MMP-9. The ELISA data for MMP-2 and MMP-9 are linear on a log:log regression curve over a wide range of MMP concentrations and are specific for the designated gelatinase, with no overlap detected with related metalloproteinases. The minimum detectable concentrations of MMP-2 and MMP-9 were approximately 0.5 ng/ml and 0.2 ng/ml, respectively, in the ELISA as compared to 4 ng/ml and 3 ng/ml, respectively, in gelatin zymography. The [3H]gelatin degradation assay required a combination of > 50 ng/ml of MMP-2 and MMP-9 for detection. Although gelatin zymography was less sensitive than ELISA (primarily due to the smaller sample volume employed) and was more difficult to quantitate, this procedure offers the important advantage of being able to distinguish between latent and activated gelatinases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8287615     DOI: 10.1007/BF01784329

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  42 in total

1.  Gelatinases of murine metastatic tumor cells.

Authors:  S Yamagata; R Tanaka; Y Ito; S Shimizu
Journal:  Biochem Biophys Res Commun       Date:  1989-01-16       Impact factor: 3.575

2.  An assay of collagenase activity using enzyme-linked immunosorbent assay for mammalian collagenase.

Authors:  H Yoshioka; I Oyamada; G Usuku
Journal:  Anal Biochem       Date:  1987-10       Impact factor: 3.365

3.  Monoclonal antibodies to human fibroblast procollagenase. Inhibition of enzymatic activity, affinity purification of the enzyme, and evidence for clustering of epitopes in the NH2-terminal end of the activated enzyme.

Authors:  B Birkedal-Hansen; W G Moore; R E Taylor; A S Bhown; H Birkedal-Hansen
Journal:  Biochemistry       Date:  1988-09-06       Impact factor: 3.162

4.  Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials.

Authors:  M Nakajima; D R Welch; P N Belloni; G L Nicolson
Journal:  Cancer Res       Date:  1987-09-15       Impact factor: 12.701

5.  H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen.

Authors:  I E Collier; S M Wilhelm; A Z Eisen; B L Marmer; G A Grant; J L Seltzer; A Kronberger; C S He; E A Bauer; G I Goldberg
Journal:  J Biol Chem       Date:  1988-05-15       Impact factor: 5.157

6.  Properties of radiolabeled type I, II, and III collagens related to their use as substrates in collagenase assays.

Authors:  K A Mookhtiar; S K Mallya; H E Van Wart
Journal:  Anal Biochem       Date:  1986-11-01       Impact factor: 3.365

7.  Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase.

Authors:  M S Hibbs; K A Hasty; J M Seyer; A H Kang; C L Mainardi
Journal:  J Biol Chem       Date:  1985-02-25       Impact factor: 5.157

8.  Human hepatoma cells produce an 85 kDa gelatinase regulated by phorbol 12-myristate 13-acetate.

Authors:  S Masure; A Billiau; J Van Damme; G Opdenakker
Journal:  Biochim Biophys Acta       Date:  1990-09-24

9.  Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells.

Authors:  E J Bernhard; R J Muschel; E N Hughes
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

10.  Malignant cell-specific gelatinase activity in human endometrial carcinoma.

Authors:  M Takemura; C Azuma; T Kimura; Y Tokugawa; M Miki; M Ono; F Saji; O Tanizawa
Journal:  Cancer       Date:  1992-07-01       Impact factor: 6.860

View more
  6 in total

1.  Development of a solid-phase assay for analysis of matrix metalloproteinase activity.

Authors:  Janelle L Lauer-Fields; Hideaki Nagase; Gregg B Fields
Journal:  J Biomol Tech       Date:  2004-12

2.  Divergent patterns of matrix metalloproteinase activity during wound healing in ileum and colon of rats.

Authors:  W F Seifert; T Wobbes; T Hendriks
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

3.  Antiphotoaging properties of Zingiber montanum essential oil isolated by solvent-free microwave extraction against ultraviolet B-irradiated human dermal fibroblasts.

Authors:  Abhiruj Navabhatra; Rawiwan Maniratanachote; Bancha Yingngam
Journal:  Toxicol Res       Date:  2021-10-03

4.  Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma.

Authors:  C F Sier; F J Kubben; S Ganesh; M M Heerding; G Griffioen; R Hanemaaijer; J H van Krieken; C B Lamers; H W Verspaget
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

5.  Wound Fluid Matrix Metalloproteinase-9 as a Potential Predictive Marker for the Poor Healing Outcome in Diabetic Foot Ulcers.

Authors:  Punyanuch Jindatanmanusan; Sivat Luanraksa; Tanit Boonsiri; Thirayost Nimmanon; Pasra Arnutti
Journal:  Patholog Res Int       Date:  2018-10-16

Review 6.  Matrix metalloproteinase-9 as a messenger in the cross talk between obstructive sleep apnea and comorbid systemic hypertension, cardiac remodeling, and ischemic stroke: a literature review.

Authors:  Saif Mashaqi; Heidi M Mansour; Hanan Alameddin; Daniel Combs; Salma Patel; Lauren Estep; Sairam Parthasarathy
Journal:  J Clin Sleep Med       Date:  2021-03-01       Impact factor: 4.062

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.